Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C29H30FN3O.ClH |
| Molecular Weight | 492.027 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.FC1=CC=C(CC2=NN(C3CCCN(CCC4=CC=CC=C4)CC3)C(=O)C5=C2C=CC=C5)C=C1
InChI
InChIKey=KBNISKYDAJMVNI-UHFFFAOYSA-N
InChI=1S/C29H30FN3O.ClH/c30-24-14-12-23(13-15-24)21-28-26-10-4-5-11-27(26)29(34)33(31-28)25-9-6-18-32(20-17-25)19-16-22-7-2-1-3-8-22;/h1-5,7-8,10-15,25H,6,9,16-21H2;1H
FLEZELASTINE, a phthalazinone derivative, an anti-asthmatic/anti-allergic agent. It exhibits inhibition of histamine release and 5-lipoxygenase, calcium antagonistic properties and antagonism at the histamine H1 receptor. FLEZELASTINE is a racemate consisting of (+)- and (-)-enantiomers. Both enantiomers contribute to the pharmacodynamic efficacy of racemic flezelastine.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
60431
Created by
admin on Mon Mar 31 18:11:39 GMT 2025 , Edited by admin on Mon Mar 31 18:11:39 GMT 2025
|
PRIMARY | |||
|
110406-33-2
Created by
admin on Mon Mar 31 18:11:39 GMT 2025 , Edited by admin on Mon Mar 31 18:11:39 GMT 2025
|
PRIMARY | |||
|
DTXSID30911635
Created by
admin on Mon Mar 31 18:11:39 GMT 2025 , Edited by admin on Mon Mar 31 18:11:39 GMT 2025
|
PRIMARY | |||
|
7DAMTNUI2A
Created by
admin on Mon Mar 31 18:11:39 GMT 2025 , Edited by admin on Mon Mar 31 18:11:39 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
